calcitonin gene-related peptide receptor antagonists
Monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, which reduces the neuroinflammatory and vasodilatory effects of CGRP.
Reduction in frequency of migraines.
Absorption: IV administration results in compete bioavailability.
Distribution: Minimally distributed to tissues.
Metabolism and Excretion: Degraded by enzymatic proteolysis into small peptides and amino acids.
Half-life: 27 days
TIME/ACTION PROFILE (plasma concentrations)
|IV||rapid||end of infusion||unknown|
- Serious hypersensitivity.
Use Cautiously in:
- OB: Safety not established in pregnancy;
- Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
- Pedi: Safety and effectiveness not established in children.
Adverse Reactions/Side Effects
Misc: HYPERSENSITIVITY REACTIONS (including anaphylaxis and angioedema)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
IV (Adults): 100 mg every 3 mo; some patients may benefit from 300 mg every 3 mo.
Solution for injection: 100 mg/mL
- Assess frequency and intensity of migraines.
- Monitor for signs and symptoms of hypersensitivity reactions (rash, angioedema, urticaria, facial flushing anaphylaxis) during and after infusion. If reaction is severe, discontinue eptinezumab and treat as needed.
- Chronic pain (Indications)
- Intermittent Infusion: Dilution: For 100 mg dose, withdraw 1 mL eptinezumab and dilute in 100 mL 0.9% NaCl. For 300 mg dose, withdraw 1 mL eptinezumab from each of 3 vials and dilute in 100 mL 0.9% NaCl. Gently invert to mix; do not shake. Infusion bags must be made of polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO). Solution is clear to slightly opalescent, colorless to brownish-yellow; do not infuse solutions that are cloudy, discolored, or contain particulate matter. Infuse within 8 hr.
- Rate: Infuse over 30 min through a 0.2 micron or 0.22 micron in-line or add-on sterile filter. Flush line with 20 mL of 0.9% NaCl.
- Instruct patient to notify health care professional immediately if signs and symptoms of hypersensitivity reaction (swelling of face, mouth, tongue or throat, trouble breathing, rash) occur.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Decrease in frequency and intensity of migraines.
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Complete Product Information.